BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) and Ikaria Inc. today began the safety and efficacy Phase I clinical trial of its BL-1040 device for the prevention of cardiac remodeling following a heart attack. The trial for EU CE Mark registration, began in Australia, and will be followed in Europe, and later in Israel and other countries.
Ikaria acquired the license for continuing the development and commercialization of BL-1040 from BioLineRx in July 2009. It is now leading BL-1040's clinical development as Bioabsorbable Cardiac Matrix (BCM), previously named IK-5001.
The trial will include 300 patients at 45 hospitals, including 50 Australians at 11 hospitals. The BL-1040 cardiac matrix will be given to patients who had successful percutaneous coronary intervention with stents after a heart attack. The patients will be monitored for six months.
BioLineRX CEO Dr. Kinneret Savitsky expects the results from the Phase I trial in 2013.
BiolineRX's share price rose 0.5% by mid-afternoon on the TASE today to NIS 1.17, after closing at $3.17 on Nasdaq on Friday, giving a market cap of $42 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 3, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012